<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01420653</url>
  </required_header>
  <id_info>
    <org_study_id>AFT-MX-6</org_study_id>
    <nct_id>NCT01420653</nct_id>
  </id_info>
  <brief_title>Maxigesic 325 Acute Dental Pain Study</brief_title>
  <official_title>Maxigesic 325 Acute Dental Pain Study: A Double-blind, Placebo-controlled, Randomized, Parallel Group Comparison of the Effects of Maxigesic 325 Versus Acetaminophen, Ibuprofen and Placebo in Participants With Acute Dental Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AFT Pharmaceuticals, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AFT Pharmaceuticals, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the analgesic effects of Maxigesic USA are
      greater than acetaminophen, ibuprofen or placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The combination of 500mg acetaminophen and 150mg ibuprofen has been shown to improve
      analgesia compared with the individual components, when given as 2 tablets (i.e. total of
      1,000/300 mg) 4 times a day.

      Recent concerns over the safety of acetaminophen have led to some regulatory agencies
      restricting the maximum dose of acetaminophen per tablet to 325 mg, while maintaining the
      maximum daily dose of 4000mg per day.

      A dosing regimen of three tablets of Maxigesic 325 four times a day gives a total daily dose
      of 3900mg acetaminophen and 1170mg ibuprofen.

      The primary objective of the study is to compare time-adjusted SPID of the VAS pain intensity
      scores up to 48 hours after the first dose of study medication among the four study groups.

      Secondary objectives are:

      To compare the time to onset of pain relief after the first dose of study drug defined as (i)
      perceptible and (ii) meaningful pain relief among the four study groups using the two
      stopwatch method.

      To compare the maximum VAS pain scores up to 48 hours after the first dose of study
      medication among the four study groups.

      To compare the response rates (response rate to be defined as the percentage of participants
      who reduce their pain intensity scores by at least 50% compared with the baseline VAS
      measure) among the four study groups.

      To compare the time to peak reduction in VAS pain intensity scores following the first dose
      of study medication among the four study groups.

      To compare the time to requirement for rescue medication among the four study groups.

      To compare the percentage of participants who use rescue medication among the four study
      groups.

      To compare the amount of rescue medication used (defined as number of tablets) among the four
      study groups.

      To compare the categorical global pain rating among the four study groups.

      Safety:

      To compare adverse event rates for the 48-hour study period and up to Day 30 among the four
      treatment groups.

      To compare the incidence of known specific NSAID and paracetamol side effects (e.g. GI
      ulceration or bleeding, indigestion/stomach pain, post-operative bleeding, bronchospasm, skin
      rashes, water retention, renal failure, thromboembolic events and evidence of clinical
      hepatitis) during the 48-hour study period and up to Day 30 among the four study groups.

      Planned hospital admissions and/or surgical operations for an illness or disease which
      existed before the study drug was given or the participant was randomized in the study will
      not be considered adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SPID (Summed Pain Intensity Differences)</measure>
    <time_frame>48 hours afte the first dose</time_frame>
    <description>The time-adjusted Summed Pain Intensity Differences (SPIDs) of the VAS pain intensity scores up to 48 hours after the first dose of study medication.
This was calculated from the visual analogue scale (VAS) pain intensity scores recorded during the 48 hours double blind treatment period, with the last measure taken just prior to the final dose of blinded study medication. The visual analogue scale is 100mm long with 0= no pain and 100=worst pain imaginable. The Visual Analogue Scale It is expected that treatments which can provide superior analgesic effect will demonstrate a greater Summed Pain Intensity Difference.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">408</enrollment>
  <condition>Dental Pain</condition>
  <arm_group>
    <arm_group_label>Maxigesic 325</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acetaminophen 325mg + ibuprofen 97.5mg per tablet, two tablets every 6 hours, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetaminophen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acetaminophen 325mg per tablet (standard dose acetaminophen), two tablets every 6 hours, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibuprofen 97.5mg per tablet (i.e. low dose ibuprofen), two tablets every 6 hours, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets, every 6 hours, orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maxigesic 325</intervention_name>
    <description>Maxigesic USA (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day with food for 48 hours</description>
    <arm_group_label>Maxigesic 325</arm_group_label>
    <other_name>Maxigesic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Acetaminophen 325 mg, 3 tablets four times a day, with food for 48 hours</description>
    <arm_group_label>Acetaminophen</arm_group_label>
    <other_name>paracetamol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Ibuprofen 97.5mg, three tablets four times a day, with food for 48 hours.</description>
    <arm_group_label>Ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo, three tablets four times a day, with food for 48 hours</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provides written informed consent before initiation of any study-related procedures.

          -  Males and females aged at least 10 years and not more than 60 years old on the day of
             consent.

          -  Undergoing dental surgery for the extraction of at least 2 impacted third molar teeth.

          -  A resting VAS pain intensity score at baseline (within 6 hours after the completion of
             surgery) of greater than or equal to 40 mm on a 100 mm VAS scale with 0 = no pain and
             100 = worst pain imaginable.

        Exclusion Criteria:

          -  Has taken any NSAID or acetaminophen within 12 hours prior to the stat of surgery
             other than asprin less than or equal to 150 mg/day

          -  Subjects who have received any anaesthetics within 24 hours prior to surgery

          -  Hypersensitivity to opioids

          -  Known to be pregnant or possibly pregnant

          -  Women of childbearing potential who are unwilling to take adequate contraceptive
             precautions, i.e., hormonal contraceptive, an intrauterine device, double-barrier
             method, or abstinence. A women of childbearing potential is defined as any female who
             is less than 2 years post-menopausal or has not undergone a partial or total
             hysterectomy or surgical sterilization, e.g. bilateral tubal ligation, bilateral
             oophorectomy.

          -  Women of childbearing potential who are unwilling to undergo an urine pregnancy test.

          -  Suffering from a neurological disorder relating to pain perception or any acute or
             chronic condition that, in the opinion of the investigator, makes the subject
             unsuitable from an efficacy or safety perspective.

          -  In the opinion of the investigator, unable to understand the visual analogue pain
             score or comply with the protocol requirements.

          -  Currently, or in the last 30 days, has been in a clinical trial involving another
             study drug.

          -  Currently treated with an ACE inhibitor, warfarin, steroid (other than nasal steroids
             or topical steroids with the approval of the investigator) cyclosporin, tacrolimus or
             methotrexate, or any other medication felt by the investigator to interfere with
             safety or efficacy evaluations.

          -  Participant weight &lt; 50 kg or &gt; 120 kg.

          -  Has a history of drug or alcohol abuse.

          -  Suffering from any other disease or condition which, in the opinion of the
             investigator, means that it would not be in the participants best interests to
             participant in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Currie, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Trial New Zealand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Premier Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial New Zealand</name>
      <address>
        <city>Hamilton</city>
        <state>Waikato</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Solutions Ltd.</name>
      <address>
        <city>Auckland</city>
        <zip>0622</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Clinical Trials</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>August 16, 2011</study_first_submitted>
  <study_first_submitted_qc>August 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2011</study_first_posted>
  <results_first_submitted>October 16, 2018</results_first_submitted>
  <results_first_submitted_qc>November 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 6, 2018</results_first_posted>
  <disposition_first_submitted>February 15, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>April 7, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 5, 2016</disposition_first_posted>
  <last_update_submitted>November 13, 2018</last_update_submitted>
  <last_update_submitted_qc>November 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Toothache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>455 Subjects have been consented and screened, out of which 47 subjects were screening failures and did not receive the first dose of study medication.
Among 408 subjects, 273 subjects enrolled from New Zealand sites and 135 subjects enrolled from USA site from May 2013 to Jan 2015.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Maxigesic 325</title>
          <description>Acetaminophen 325mg + ibuprofen 97.5mg per tablet, two tablets every 6 hours, orally
Maxigesic 325: Maxigesic USA (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day with food for 48 hours</description>
        </group>
        <group group_id="P2">
          <title>Acetaminophen</title>
          <description>Acetaminophen 325mg per tablet (standard dose acetaminophen), two tablets every 6 hours, orally
Acetaminophen: Acetaminophen 325 mg, 3 tablets four times a day, with food for 48 hours</description>
        </group>
        <group group_id="P3">
          <title>Ibuprofen</title>
          <description>Ibuprofen 97.5mg per tablet (i.e. low dose ibuprofen), two tablets every 6 hours, orally
Ibuprofen: Ibuprofen 97.5mg, three tablets four times a day, with food for 48 hours.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo tablets, every 6 hours, orally
Placebo: placebo, three tablets four times a day, with food for 48 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="111"/>
                <participants group_id="P3" count="112"/>
                <participants group_id="P4" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="108"/>
                <participants group_id="P3" count="108"/>
                <participants group_id="P4" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Maxigesic 325</title>
          <description>Acetaminophen 325mg + ibuprofen 97.5mg per tablet, two tablets every 6 hours, orally
Maxigesic 325: Maxigesic USA (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day with food for 48 hours</description>
        </group>
        <group group_id="B2">
          <title>Acetaminophen</title>
          <description>Acetaminophen 325mg per tablet (standard dose acetaminophen), two tablets every 6 hours, orally
Acetaminophen: Acetaminophen 325 mg, 3 tablets four times a day, with food for 48 hours</description>
        </group>
        <group group_id="B3">
          <title>Ibuprofen</title>
          <description>Ibuprofen 97.5mg per tablet (i.e. low dose ibuprofen), two tablets every 6 hours, orally
Ibuprofen: Ibuprofen 97.5mg, three tablets four times a day, with food for 48 hours.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo tablets, every 6 hours, orally
Placebo: placebo, three tablets four times a day, with food for 48 hours</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="110"/>
            <count group_id="B2" value="111"/>
            <count group_id="B3" value="112"/>
            <count group_id="B4" value="75"/>
            <count group_id="B5" value="408"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.4" spread="7.0"/>
                    <measurement group_id="B2" value="25.0" spread="6.9"/>
                    <measurement group_id="B3" value="24.3" spread="5.9"/>
                    <measurement group_id="B4" value="24.3" spread="6.3"/>
                    <measurement group_id="B5" value="24.8" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="275"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>SPID (Summed Pain Intensity Differences)</title>
        <description>The time-adjusted Summed Pain Intensity Differences (SPIDs) of the VAS pain intensity scores up to 48 hours after the first dose of study medication.
This was calculated from the visual analogue scale (VAS) pain intensity scores recorded during the 48 hours double blind treatment period, with the last measure taken just prior to the final dose of blinded study medication. The visual analogue scale is 100mm long with 0= no pain and 100=worst pain imaginable. The Visual Analogue Scale It is expected that treatments which can provide superior analgesic effect will demonstrate a greater Summed Pain Intensity Difference.</description>
        <time_frame>48 hours afte the first dose</time_frame>
        <population>Primary Efficacy Endpoint was analyzed in ITT population (subjects who have been randomized and received the first dose of study medication)</population>
        <group_list>
          <group group_id="O1">
            <title>Maxigesic 325</title>
            <description>Acetaminophen 325mg + ibuprofen 97.5mg per tablet, two tablets every 6 hours, orally
Maxigesic 325: Maxigesic USA (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day with food for 48 hours</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen</title>
            <description>Acetaminophen 325mg per tablet (standard dose acetaminophen), two tablets every 6 hours, orally
Acetaminophen: Acetaminophen 325 mg, 3 tablets four times a day, with food for 48 hours</description>
          </group>
          <group group_id="O3">
            <title>Ibuprofen</title>
            <description>Ibuprofen 97.5mg per tablet (i.e. low dose ibuprofen), two tablets every 6 hours, orally
Ibuprofen: Ibuprofen 97.5mg, three tablets four times a day, with food for 48 hours.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo tablets, every 6 hours, orally
Placebo: placebo, three tablets four times a day, with food for 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>SPID (Summed Pain Intensity Differences)</title>
          <description>The time-adjusted Summed Pain Intensity Differences (SPIDs) of the VAS pain intensity scores up to 48 hours after the first dose of study medication.
This was calculated from the visual analogue scale (VAS) pain intensity scores recorded during the 48 hours double blind treatment period, with the last measure taken just prior to the final dose of blinded study medication. The visual analogue scale is 100mm long with 0= no pain and 100=worst pain imaginable. The Visual Analogue Scale It is expected that treatments which can provide superior analgesic effect will demonstrate a greater Summed Pain Intensity Difference.</description>
          <population>Primary Efficacy Endpoint was analyzed in ITT population (subjects who have been randomized and received the first dose of study medication)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="112"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.56" spread="1.94"/>
                    <measurement group_id="O2" value="17.71" spread="1.89"/>
                    <measurement group_id="O3" value="23.18" spread="1.89"/>
                    <measurement group_id="O4" value="14.86" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent Adverse Events were collected from the randomization to the follow up telephone contact made at 30 days after the surgery (Surgery Day is Day 1)</time_frame>
      <desc>The definition of adverse event and/or serious adverse event, used to collect adverse event information is the same as the one from the clinicatrials.gov.</desc>
      <group_list>
        <group group_id="E1">
          <title>Maxigesic 325</title>
          <description>Acetaminophen 325mg + ibuprofen 97.5mg per tablet, two tablets every 6 hours, orally
Maxigesic 325: Maxigesic USA (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day with food for 48 hours</description>
        </group>
        <group group_id="E2">
          <title>Acetaminophen</title>
          <description>Acetaminophen 325mg per tablet (standard dose acetaminophen), two tablets every 6 hours, orally
Acetaminophen: Acetaminophen 325 mg, 3 tablets four times a day, with food for 48 hours</description>
        </group>
        <group group_id="E3">
          <title>Ibuprofen</title>
          <description>Ibuprofen 97.5mg per tablet (i.e. low dose ibuprofen), two tablets every 6 hours, orally
Ibuprofen: Ibuprofen 97.5mg, three tablets four times a day, with food for 48 hours.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo tablets, every 6 hours, orally
Placebo: placebo, three tablets four times a day, with food for 48 hours</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Death due gun shot</sub_title>
                <description>The death was due to the gunshot wound (homicide) occurred during 30 days follow up period and not related to the study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="111"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="110"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="111"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="112"/>
                <counts group_id="E4" events="21" subjects_affected="17" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="110"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="111"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="110"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="112"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Diziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Facial swelling</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="111"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="112"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Zhang</name_or_title>
      <organization>AFT Pharmaceuticals Ltd.</organization>
      <phone>+ 64 9 488 0232 ext 710</phone>
      <email>jenniferz@aftpharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

